Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

by Zachary Silbersher

Posts tagged '385 patent
Can Gilead dismiss ViiV’s patent lawsuit for Biktarvy?

We previously blogged about ViiV Healthcare’s ($GSK) patent lawsuit against Gilead ($GILD) when the case commenced in February 2018.  In the case, ViiV alleges that Gilead’s Biktarvy® infringes ViiV’s ‘385 patent.  The case is heading for trial in late 2020.  Before that, however, Gilead has moved to dismiss the case outright before trial.  Will Gilead succeed?  Whether or not Gilead’s motion is granted, the issues outlined below will likely form the crux of the dispositive issues in dispute.

Read More